ArticleFrontiers in nutrition2026
Predictive value of TyG-BMI, CTI, and SII in identifying metabolic dysfunction-associated steatotic liver disease among patients with type 2 diabetes mellitus.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major comorbidity in patients with type 2 diabetes mellitus (T2DM). This study aimed to evaluate the diagnostic performance of the triglyceride-glucose-body mass index (TyG-BMI), the C-reactive protein-triglyceride-glucose index (CTI), and the systemic immune-inflammation index (SII), individually and in combination, for identifying MASLD in patients with T2DM. Methods: This retrospective cross-sectional study enrolled 796 hospitalized patients with T2DM from January 2020 to January 2025. Sample size was determined based on available eligible cases during the study period. Data distribution was assessed using the Kolmogorov-Smirnov test. There were 280 MASLD patients and 516 non-MASLD patients. We collected anthropometric, biochemical, and inflammatory parameters. We performed correlation and multivariate logistic regression analyses to find independently associated factors. We evaluated diagnostic performance using receiver operating characteristic (ROC) curves, the area under the curve (AUC), and the Youden index. We also used net reclassification improvement (NRI) and integrated discrimination improvement (IDI) to assess predictive value. External validation was performed using an independent cohort of 394 patients. Key limitations include the retrospective design, potential misclassification due to ultrasound-based diagnosis, and residual confounding. Results: MASLD patients exhibited significantly higher BMI, triglycerides, low-density lipoprotein cholesterol (LDL-C), TyG-BMI, CTI, and SII levels than non-MASLD patients (all Conclusion: TyG-BMI, CTI, and SII are independently associated with MASLD in T2DM patients. Their combined use significantly improves early identification accuracy and could serve as a convenient, cost-effective screening tool in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.